Targeted pill shows promise for rare lung cancer mutation in chinese patients
NCT ID NCT04677595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block faulty signals that help cancer grow. Researchers measured how many patients' tumors shrank or disappeared.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capmatinib (oral targeted therapy)
What this could lead to
If successful, this could provide a new targeted treatment option for Chinese patients with this specific type of lung cancer.
What could go wrong
This is a small Phase 2 study with only 36 participants, so results may not apply to all patients. The drug may not work as well in a broader population or may have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Xiamen, Fujian, 361001, China
-
Novartis Investigative Site
Foshan, Guangdong, 528000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 524000, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150000, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450003, China
-
Novartis Investigative Site
Wuhan, Hubei, 430024, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110001, China
-
Novartis Investigative Site
Jinan, Shandong, 250117, China
-
Novartis Investigative Site
Shanghai, Shanghai Municipality, 200030, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Kunming, Yunnan, 650106, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100142, China
-
Novartis Investigative Site
Shanghai, 200030, China
-
Novartis Investigative Site
Tianjin, 300052, China